Tecentriq

Atezolizumab, sold as Tecentriq by Genentech (a Roche subsidiary), is a PD-L1 blocking antibody approved across five tumor types: non-small cell lung cancer (NSCLC), small cell lung cancer, hepatocellular carcinoma, BRAF V600-mutant melanoma, and the rare soft-tissue cancer alveolar soft part sarcoma. The drug pulled in $4.0B in 2025 revenue [1], roughly flat year over year. Roche does not disclose Tecentriq revenue by indication in its public filings, so a true franchise-level breakdown (HCC vs. ES-SCLC vs. adjuvant NSCLC) is not possible from external data. Merck's Keytruda continues to dominate the checkpoint-inhibitor class with revenue several times that figure [2]. In September 2024 the FDA cleared Tecentriq Hybreza under BLA 761347 [3], a subcutaneous formulation that compresses infusion visits from an hour to about seven minutes. That approval was a defensive move to keep clinicians on the Roche brand ahead of biosimilar pressure in the early 2030s, but its competitive window has already narrowed: FDA approved Keytruda Qlex, Merck's subcutaneous pembrolizumab, in September 2025 [14]. The commercial story now is not growth. It is holding share in a class that has consolidated around three winners.

First FDA approval came in May 2016 under accelerated approval for metastatic urothelial carcinoma (UC) via BLA 761034, making atezolizumab the first PD-L1 inhibitor ever cleared [4]. That inaugural second-line post-platinum UC indication was voluntarily withdrawn in March 2021 after the IMvigor211 confirmatory trial failed to show an overall survival benefit [15]; a separate first-line cisplatin-ineligible UC indication was withdrawn on November 29, 2022 following IMvigor130 results [15]. The triple-negative breast cancer indication, paired with nab-paclitaxel on the strength of IMpassion130 [5], was pulled in August 2021 after IMpassion131 missed its primary endpoint. What remains is a durable five-indication portfolio: NSCLC (first-line monotherapy in high PD-L1 expressers, and adjuvant stage II-IIIA settings), extensive-stage small cell lung cancer in combination with carboplatin and etoposide, first-line hepatocellular carcinoma with bevacizumab, BRAF V600-mutant melanoma with cobimetinib and vemurafenib, and alveolar soft part sarcoma as a rare-cancer monotherapy. In September 2024, FDA approved Tecentriq Hybreza under BLA 761347 [3], a subcutaneous formulation injected in roughly seven minutes versus the 30-60 minute IV infusion. No US biosimilar has been filed. European and Asian biosimilar programs are more advanced given earlier composition-of-matter expirations in some jurisdictions and ongoing development in India and China, which is material to Roche's ex-US Tecentriq revenue. The main US composition-of-matter protection runs into the early 2030s, with method-of-use and formulation patents extending beyond. Supply is stable, with no REMS program attached.

T cells, the immune system's assassins, come wired with a safety switch. The receptor is called PD-1, and its job is to stop T cells from attacking healthy tissue. Tumors have figured out how to exploit this. They cover their surface in a protein called PD-L1 [6], which clicks into PD-1 like a key into a lock and tells the T cell to stand down. Atezolizumab is an engineered antibody that binds to PD-L1 on the tumor surface, physically blocking it from engaging PD-1. The brake no longer presses, and the T cell is free to kill. Most other checkpoint inhibitors (Merck's pembrolizumab, BMS's nivolumab) block PD-1 on the T cell instead of PD-L1 on the tumor. The distinction matters in theory. PD-1 has a second ligand, PD-L2, which also signals through the same receptor; blocking PD-L1 only leaves the PD-L2/PD-1 pathway intact, which may preserve some tolerance signaling and reduce certain autoimmune side effects. In practice, clinical safety profiles across the class look similar in community use, and no head-to-head trial has demonstrated a meaningful efficacy difference between PD-1 and PD-L1 inhibitors. What makes some patients respond and others not comes down to a few variables. Tumors with heavy PD-L1 expression tend to respond better, which is why NSCLC approvals are stratified by PD-L1 immunohistochemistry (IHC) staining. Tumor mutational burden also matters. Cancers with many mutations (lung, melanoma, bladder) generate more neoantigens for the immune system to recognize once the brake is lifted. Cold tumors with few mutations and sparse immune infiltrate largely do not respond, no matter how much PD-L1 is blocked. Combinations with chemotherapy, anti-VEGF agents like bevacizumab, or targeted therapy exist precisely to warm those tumors up by killing some cancer cells and dumping their contents into the surrounding tissue before the T cells are released.

Three readouts built the current label. IMpower133 in extensive-stage SCLC paired atezolizumab with carboplatin and etoposide, extending median overall survival from 10.3 to 12.3 months with a hazard ratio of 0.70 [7]. A hazard ratio of 0.70 means patients on atezolizumab died at 70% the rate of the control group at any given moment in follow-up, a 30% reduction in the instantaneous risk of death. That was the first meaningful overall survival improvement in SCLC in roughly 20 years. IMpower150 in nonsquamous NSCLC added atezolizumab plus bevacizumab to carboplatin and paclitaxel and delivered median overall survival of 19.2 months versus 14.7 months in the chemo-plus-bevacizumab arm, hazard ratio 0.78 [8]. The benefit held in EGFR-mutant and liver-metastasis subgroups, two populations that generally do poorly on checkpoint monotherapy. IMbrave150 in unresectable hepatocellular carcinoma combined atezolizumab with bevacizumab and beat sorafenib on both overall survival (hazard ratio 0.58) and progression-free survival (hazard ratio 0.59) [9], displacing a decade-old standard of care. Recent real-world data in HCC confirm the trial efficacy, with sequential radioembolization followed by atezolizumab-bevacizumab further improving survival in selected patients [10]. Note on terminology: first-line (1L) means initial systemic therapy for metastatic or advanced disease; second-line and later (2L+) means treatment after at least one prior regimen has failed. Safety is standard immuno-oncology territory: immune-mediated pneumonitis, colitis, hepatitis, endocrinopathies (thyroid, adrenal, pituitary), and infusion reactions. The label carries no black box but documents severe and fatal immune-related adverse events. Community-practice discontinuation rates for toxicity run modestly higher than registration-trial populations, which is typical for the class.

Atezolizumab is a solid number three or four in a class that Keytruda (pembrolizumab, Merck) and Opdivo (nivolumab, BMS) have run away with. Keytruda alone cleared roughly $29B in 2024 revenue [2], several times Tecentriq's take, with head-to-head perception favoring pembrolizumab for first-line NSCLC monotherapy and broader label breadth. Durvalumab (Imfinzi, AstraZeneca) owns stage III unresectable NSCLC after chemoradiation and, following CASPIAN, has become the primary competitor to IMpower133 in extensive-stage SCLC with chemo; both regimens are listed as Category 1 options in NCCN guidelines, and durvalumab has steadily taken community share through the early 2020s. Nivolumab remains the leader in melanoma and gastric cancer. Atezolizumab's two defensible franchises are first-line hepatocellular carcinoma with bevacizumab, where IMbrave150 remains the control arm every competitor has to beat, and extensive-stage SCLC with chemo, where IMpower133 opened the door that durvalumab later walked through. US composition patents extend into the early 2030s, with formulation and method-of-use patents running longer. The Hybreza subcutaneous launch in September 2024 was explicitly a life-cycle extension play. Its convenience edge has already been neutralized: FDA approved Keytruda Qlex (subcutaneous pembrolizumab with berahyaluronidase alfa) in September 2025 across most adult solid-tumor indications [14], meaning community oncologists no longer need to switch to Tecentriq for a subcutaneous checkpoint option. Biosimilars are in active development in India and China, where composition-of-matter protection is weaker or has lapsed; several ex-US launches are plausible before the US patent cliff. No US biosimilar filings have been accepted to date.

Revenue has essentially plateaued. Tecentriq delivered $4.0B in 2025 [1], holding roughly flat for several years, as modest additions (alveolar soft part sarcoma, adjuvant NSCLC via IMpower010, the melanoma triplet) have offset the loss of urothelial carcinoma and TNBC. Roche does not break out Tecentriq revenue by indication in its public filings, so an indication-level trajectory analysis (HCC franchise strength vs. SCLC share loss to durvalumab vs. adjuvant NSCLC growth) is not possible from external data; the 'plateaued' characterization cannot be stress-tested without that disclosure. The pre-computed probability-of-success score of 99% reflects that this is a Phase 4, five-indication approved asset backed by a top-quartile sponsor. The model is scoring commercial survival, not trial success. The real risk is competitive erosion, not clinical failure. Twelve-to-eighteen-month catalysts worth watching: the NCI-sponsored AASI-NSCLC Phase 3 postoperative study (NCT07388524) could extend adjuvant positioning if positive [11]; the NCI neuroendocrine carcinoma Phase 2 (NCT05058651) is a lower-probability but underserved indication [12]. The previously anticipated Keytruda SC approval has already landed (September 2025) [14], which removes a catalyst and converts a prospective threat into a realized one. Policy pressure on checkpoint inhibitor dosing (recent work argues for weight-based or extended-interval regimens to cut costs) could compress revenue if adopted at scale [13]. For Roche, Tecentriq is a $4B franchise against a $72B total pharma top line, meaningful but not thesis-defining. The thesis changes further if a US biosimilar is filed earlier than expected, if IMbrave150's HCC combo is displaced by a bispecific or TKI-plus-IO regimen now in Phase 3, or if European and Asian biosimilar launches accelerate the ex-US erosion curve.